Riding the Wave or Caught in the Tide? Strategies in the Wake of the New USPTO Guidelines on the Patent Eligibility of Isolated Natural Products

The USPTO has issued controversial new guidelines for the examination of claims to isolated natural products. Please join us for an interactive discussion on patenting strategies and validity assessments in view of these guidelines and in the wake of the Supreme Court’s Myriad and Mayo decisions. During this program we will provide updates on recent developments involving 35 U.S.C. § 101 before the U.S. Patent and Trademark Office (USPTO), Patent Trial and Appeal Board (PTAB), district and federal courts, and consider strategies for assessing validity and patenting claims directed to natural products, pharmaceutical compositions, products containing nucleic acids, and diagnostic methods.

Finnegan attorneys will discuss additional topics, including:

• An analysis of the new USPTO guidance on 35 U.S.C. § 101 
• An analysis of recent developments in cases before district courts and the U.S. Court of Appeals for the Federal Circuit involving 35 U.S.C. § 101 and natural products and/or diagnostic methods

There is no charge to attend. Due to space limitations, please register early.

Speakers:

Leslie A. McDonell
Jeffrey M. Jacobstein
Alissa K. Lipton
Lulu Wang, Ph.D.

Date:

Thursday, March 20, 2014

Time:

2:45 - 3:00 p.m. - Registration
3:00 - 5:00 p.m. - Program
5:00 - 6:00 p.m. - Reception

Location:

Finnegan
Two Seaport Lane
Boston, MA 02210